Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III

French Innovative Leukemia Organisation232 enrolled

Overview

Improved outcome of high risk lymphoblastic leukemia (ALL) with laite high dose therapy. High dose versus conventional therapy for adult low risk T-ALL and Lymphoblastic lymphoma (LBL).

Comparison between two autograf therapeutic strategies in high risk patients Ramdomised comparison between maintenance treatment with or not interferon alpha 2 a

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

232

Conditions

Leukemia, Lymphocytic, Acute

Interventions

interferon alpha 2aDRUG

Eligibility

Sex: ALLMin age: 15 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria * ALL high risk or low risk or lymphoblastic lymphoma * age 15-55 years old * informed consent signed Exclusion Criteria: * patients previously treated with a chemotherapy or alpha-interferon * ALL 3 (burkitt like)

Locations (1)

INorbert IFRAH

Angers, Chu Angers, France

Outcomes

Primary Outcomes

overall survival

Time frame: time to death

Secondary Outcomes

Efficacy of study treatments

Time frame: time to end of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.